(Source: Santhera Pharmaceuticals Holding AG) Liestal, Switzerland, July 20, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces that the first patient in the CALLISTO Phase I study assessing the pharmacokinetics, safety and tolerability of oral omigapil in patients with Congenital Muscular Dystrophy (CMD) has been dosed and all participating patients have been recruited. This study, which is being conducted at the US National Institutes of Health (NIH), will also evaluate the feasibility of conducting disease-relevant clinical assessments that could be used as endpoints in future efficacy trials in pediatric and adolescent CMD patients. Omigapil is a drug candidate in-licensed from...
↧
